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Purpose: Behavioral and psychiatric symptoms of dementia (BPSD) are common in Alzheimer’s 
disease (AD) and disrupt the effective management of AD patients. The present study explores 
the use of radio electric asymmetric brain stimulation (REAC) in patients who have had a poor 
response to pharmacological treatment.
Patients and methods: Eight patients (five females and three males; mean [±  standard deviation] 
age at study baseline: 69.9 ± 3.0 years) diagnosed with AD according to the DSM-IV-TR criteria 
(mean onset age of AD: 65.4 ± 3.5 years) were cognitively and   psychometrically assessed 
with the Mini-Mental State Examination (MMSE), the Activity of Daily Living (ADL), the 
Instrumental Activity of Daily Living (IADL), and the Neuropsychiatric Inventory (NPI), prior 
to and after each of 2 REAC treatment cycles.
Results: Scores on the MMSE and all subscales of the NPI (frequency, severity, and distress), 
the ADL, and the IADL were significantly improved following the initial REAC treatment. There 
was further significant improvement in all measurements (with a tendency for improvement in 
the IADL) after the second REAC treatment cycle.
Conclusion: The improvement of cognitive and behavioral/psychiatric functioning following 
REAC treatment suggests that this innovative approach may be an effective, safe, and tolerable 
alternative to pharmacological treatment of AD patients, especially in the area of BPSD. Elderly 
patients suffering from other types of dementia may also benefit from REAC treatment.
Keywords: anxiety, depression, insomnia, behavioral and psychiatric symptoms of 
dementia (BPSD)
Introduction
The progressively increasing number of the elderly in the general population and, 
consequently, the growing prevalence of Alzheimer disease1,2 (AD) highlight the 
need for new specifically targeted therapeutic options.3–6 The currently available 
psychological7–10 and psychopharmacological11–15 treatments16 for AD provide relatively 
poor results. The inadequate and/or insufficient safety and tolerability profile of ‘typical’ 
AD therapies produce familiar social and economic difficulties.17,18 According to the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR), AD includes a disruption in attention,19,20 concentration, memory,21,22 
and cognition.23 While the DSM-IV-TR instructs diagnosing clinicians to specify 
whether cognitive symptoms of AD are accompanied by behavioral abnormalities 
(eg, delusions, depression, anxiety, agitation, wandering, sexual behavior alterations, 
sleep dysfunctions, disorientation), behavioral symptoms of AD are not included in 
the working definition.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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The relationship between AD and the behavioral and 
psychiatric symptoms of dementia24 (BPSD) is becoming 
more prevalent. Symptoms of dementia accompany AD in 
about 90% of cases,25 typically arising early in the course 
of the disease and persisting. Unlike the steady loss of 
“global” cognition, throughout the course of AD, behavioral 
symptoms are more variable, with different types of BPSD 
seen among patients.26 Despite the observed inter-patient 
variability in number and type of behavioral symptoms 
encountered in AD, patients with advanced illness tend to 
have more behavioral symptoms than those in earlier phases 
of the disorder. Several long-term studies indicate that once 
a specific symptom occurs in a given patient, it is likely to 
persist or recur thereafter.
Radio electric asymmetric brain stimulation27,28 (REAC) 
treatment has proven efficacy in ameliorating several 
stress-related disorders, depression, and anxiety,29–35 and 
our unpublished data have shown promising results for 
some forms of dementias. REAC treatments are painless, 
noninvasive, and have a high safety and tolerability profile. 
On the basis these we can hypothesize that the treatments with 
REAC technology may be helpful in AD and, in general, in 
several forms of cognitive-impairment disorders.
Aim of the present study
REAC has demonstrated efficacy in improving certain psy-
chiatric disorders such as anxiety, depression and bipolar 
disorder. The main goal of the present study was to inves-
tigate the efficacy of REAC in the treatment of behavioral 
symptoms in AD patients. In addition, effects on cognitive 
functioning were also investigated.
Materials and methods
The data for the current study were collected during routine 
therapy sessions at the Rinaldi Fontani Institute, Behavioral 
Disorder Department in Florence, Italy. Most patients referred 
to the clinic were nonresponders to typical pharmacological 
strategies. Eight patients (five females and three males; mean 
[±SD] age at study baseline: 69.9 ± 3.0 years) diagnosed with 
AD according to the DSM-IV-TR criteria (mean onset age 
of AD: 65.4 ± 3.5 years), presenting with behavioral and/
or   psychiatric disturbances were psychometrically assessed 
using the Mini-Mental State Examination36 (MMSE), the 
Activity of Daily Living37 (ADL), the Instrumental Activity 
of Daily Living38 (IADL), and the Neuropsychiatric Inven-
tory39 (NPI), before and after 2 treatment cycles of REAC.
REAC is applied by a medical device that is based on an 
innovative biostimulation technology.27,28 REAC works within 
a typical frequency range of 2.4, 5.8, or 10.5 GHz, selected 
by the operator for each specific protocol. For the current 
study, a frequency of 10.5 GHz, with a specific absorption rate 
(SAR) of 7 µW/kg, was used. The neuro postural optimization 
(NPO) protocol consisting of a single radiofrequency burst 
of 500 milliseconds (ms) applied by touching the metallic tip 
of the REAC probe (Convogliatore di Radianza Modulante – 
CRM; ASMED, Italy) to the ear pavilion was performed as 
an initial treatment. NPO was followed by another treatment 
protocol, named neuro psycho physical optimization (NPPO). 
This protocol consisting of seven REAC radiofrequency 
bursts of 500 ms applied by touching the metallic tip of 
Table 1 Total score variation before and after first REAC treatment cycle
Test TSV before  
REAC
TSV after  
1 REAC cycle
ANOVA  
F
df P
MMse 18.5 ± 2.4 23.4 ± 2.3 64.0588 14 ,0.01
NPI for “frequency” 32.2 ± 2.5 26.4 ± 2.4 309.8421 14 0.000
NPI for “severity” 28.6 ± 3.4 22.1 ± 3.4 529.000 14 0.000
NPI for “distress” 49.5 ± 3.6 41.0 ± 2.1 583.1538 14 0.000
ADL   3.8 ± 1.0   4.9 ± 0.5 33.8507 14 Ns
IADL 10.0 ± 2.4 13.0 ± 1.1 134.8667 14 0.000
Abbreviations: reAC, radio electric asymmetric brain stimulation; Tsv, total score variation; MMse, Mini-Mental state examination; NPI, Neuropsychiatric inventory;   
ADL, Activity of Daily Living; IADL, Instrumental Activity of Daily Living; NS, not statistically significant.
18.5
23.4 26
0
5
10
15
20
25
30
T
o
t
a
l
 
s
c
o
r
e
 
v
a
r
i
a
t
i
o
n
 
(
T
S
V
)
Before REAC After 1st REAC cycle After 2nd REAC cycle
Figure 1 Mini-Mental State Examination (MMSE) before, after the first and second 
reAC treatment cycle. 
Abbreviations:  reAC,  radio  electric  asymmetric  brain  stimulation;  Tsv,  total 
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the REAC probe at precise points of the ear. Each therapy 
session lasts about 5 seconds. An NPPO treatment cycle 
consists of 18 therapy sessions, administered on alternate 
days. The mean interval between the first and the second 
NPPO treatment cycle is about 6 months.
ANOVA for repeated measures was performed for 
statistical analysis of differences in MMSE, ADL, IADL, 
and NPI scores prior to and following REAC treatments. 
P values ,0.05 were considered significant.
Results
After the first REAC treatment cycle, patients showed great 
improvement in cognitive performance as demonstrated by 
a significant increase in average MMSE total score from 
18.5 (±2.4) to 23.4 (±2.3) (ANOVA P , 0.01) (Table 1 and 
Figure 1). In addition, BPSD was improved as demonstrated 
by a decrease in average NPI frequency score (Table 1 
and Figure 2) from 32.2 (±2.5) to 26.4 (±2.4) (ANOVA 
P = 0.000), NPI severity score (Table 1 and Figure 2) from 
28.6 (±3.4) to 22.1 (±3.4) (ANOVA P = 0.000), and NPI 
distress score from (Table 1 and Figure 2) 49.5 (±3.6) to 
41.0 (±2.1) (ANOVA P = 0.000). In addition, average ADL 
score (Table 1 and Figure 3) increased from 3.8 (±1.0) to 4.9 
(±0.5) (ANOVA P = NS) and average IADL score (Table 1 
and Figure 4) increased from 10.0 (±2.4) to 13.0 (±1.1) 
(ANOVA P = 0.000).
After the second REAC treatment cycle, there were 
  further significant ameliorations in both cognitive and 
  behavioral performance (Table 2). There was a significant 
increase in average MMSE total score (Table 2 and   Figure 1) 
to 26.0 (±3.4) (ANOVA P , 0.001), and a significant 
decrease in NPI frequency score (Table 2 and Figure 2) 
to 23.3 (±2.3) (ANOVA P , 0.001), NPI severity score 
(Table 2 and Figure 2) to 18.2 (± 3.7) (ANOVA P = 0.000), 
and NPI   distress score (Table 2 and Figure 2) to 36.7 (±4.3) 
(ANOVA P = 0.000). IADL total score was significantly 
increased after the second REAC treatment to 14.4 (±0.7) 
(ANOVA P = NS) (Table 2 and Figure 4). The increase in 
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Figure 2 Neuro Psychiatric Inventory (NPI) before after first and second REAC treatment cycle.
Abbreviation: reAC, radio electric asymmetric brain stimulation.
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Figure 3 Activity of Daily Living (ADL), before, after first and second reAC   
treatment cycle. 
Abbreviation: reAC, radio electric asymmetric brain stimulation.
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Figure 4 Instrumental Activity of Daily Living (IADL), before, after first and second 
reAC treatment cycle. 
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ADL total score to 5.1 ± 0.4 (Table 2 and Figure 3) was not 
statistically significant (ANOVA P = NS).
Discussion
REAC treatment enhanced cognitive and behavioral 
functioning in patients with AD. All measures of cognitive 
functioning were significantly improved after the initial 
REAC treatment and continued to improve after the second 
REAC cycle. Similarly, all behavioral measurements were 
positively affected after the first REAC treatment and most 
continued to improve after the second cycle.
It is likely that the effects on cognition and behavior are 
due to a process of synchronization of brain function caused 
by the microelectric stimulation of the REAC.29
While cognitive functioning benefitted from REAC 
treatment, the positive effects on BPSD may be of more 
importance in the management of AD patients. The 
improvement in these clinical parameters is reflected in 
functional terms by an increase in the quality of life of 
patients as reported by relatives, physicians, and care-
givers and is psychometrically demonstrated by the ADL 
and IADL total scores. The use of REAC treatment may 
decrease the need to continually alter pharmacological 
treatments to achieve optimal results, leading to significant 
savings in economic resources of rehabilitation programs 
for AD patients.
REAC treatments alone are not likely to manage all 
  deficits associated with neuropsychiatric disorders in the 
elderly. However, the results of the present study suggest 
that REAC treatment has a high safety, tolerability, and 
efficacy profile and may be useful not only in patients 
who have experienced poor and/or unstable responses to 
  psychotropic drugs, but also as a first-line therapeutic option. 
REAC treatment may be useful not only for AD patients, 
but also for other forms of dementia (ie, vascular dementia 
or mixed conditions).
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